The task force represents diverse stakeholders from across the clinical research ecosystem, including representatives from academic medical centers and universities, biotechnology and pharmaceutical companies, AI technology researchers, and IRB ethicists, members, and chairs.
Tag Archive for: clinical research
The healthcare industry is acutely aware of the elevated compliance concerns involved with artificial intelligence and machine learning, and its governing organizations are taking swift action to address these challenges. In fact, the latest guidelines proposed by international regulatory organizations such as the FDA, European Union (EU), and European Medicines Agency (EMA) are poised to reshape the lifesciences industry, especially for clinical trials.
Biomedical research, the bedrock of medical advancements on Earth, has always been a maze of challenges. From the complexities of human biology to the unpredictability of diseases, researchers are in a constant battle with variables that can alter the course of a study. But what if there was a way to sidestep some of these Earth-bound limitations? This is where space, the next frontier in clinical research, comes into play.
The importance of diversity in clinical research has gained significant recognition, driven by its potential to reduce healthcare disparities, enhance patient outcomes, enrich medical education, and broaden research methodologies. However, consistent underrepresentation of racial and ethnic minorities in clinical trials poses a barrier to the generalizability of research findings.
Predictions from Pamela Tenaerts, M.D., chief scientific officer and Alison Holland, executive GM of customer value, Medable.
Rohit Nambisan and Andreas Matern of Lokavant share insights on where they see AI in clinical research and personalized medicine development next year.
Real-world data (RWD) improves health care – especially patient safety. The data enhances signal detection and management to identify and evaluate potential safety concerns. While it offers many advantages over traditional data sources for pharmacovigilance, simply having data is not enough. For optimal utility, healthcare entities must use effective data management tools.
Whether you’re an oncologist directing cancer care, or a health creative communicating science, the most consequential decisions are always human. Tech brainpower can inform our choices, but it takes empathy and real-world understanding to figure out what works best. And the question of how health can maximize AI continues to stoke debate.
Diversity and inclusion are important pillars of the healthcare industry, especially within the clinical research space. To ensure the best overall patient care, it is critical to have an appropriate representation of the populations being researched. Understanding why and how minority populations are underrepresented allows pharmaceutical sponsors and CROs to outline actionable steps to create more diverse and equitable trials.
The new additions to Abbott’s Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company’s own clinical trials during the initiative’s first year.